Lancashire and South Cumbria
Formulary
Formulary
1 Gastro-intestinal system
01-05-03 Tumor necrosis factor alpha (TNF-a) inhibitors
| Infliximab |
|
Formulary
|
Intravenous infusion 100mg Adequate resuscitation facilities must be available when infliximab is used. Use in high risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery. Acute exacerbations of Ulcerative Colitis - NICE TA163 Moderate to severe active ulcerative colitis - NICE TA329 For Treatment of immuno-oncology induced colitis/diarrhoea after failure of steroid treatment see section 08.01. |
 NICE TA163: Infliximab for acute exacerbations of ulcerative colitis NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
|
| Adalimumab |
|
Formulary
|
Pre-filled syringe or pen Crohn's disease - NICE TA187 Ulcerative colitis - NICE TA329 High risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery |
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
|
|
| Golimumab |
|
Formulary
|
Pre-filled syringe or pen Moderate to severe active ulcerative colitis |
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
|
|
| Adalimumab |
|
Formulary
|
Prevention of recurrence of ulcerative colitis following surgery |
|
LSCMMG: Adalimumab |
|
| Certolizumab pegol |
|
Formulary
|
Do not prescribed for Crohn's disease or ulcerative colitis |
|
LSCMMG: Certolizumab Pegol Crohn’s disease LSCMMG: Certolizumab Pegol Ulcerative Colitis |
|
|
| Golimumab |
|
Formulary
|
Prevention of recurrence of ulcerative colitis following surgery |
|
LSCMMG: Golimumab |
|
|
Links
- LSCMMG: Adalimumab
LSCMMG: Azathioprine and Mercaptopurine shared care guideline- LSCMMG: Azathioprine and Mercaptopurine shared care guideline
- LSCMMG: Certolizumab Pegol Crohn’s disease
- LSCMMG: Certolizumab Pegol Ulcerative Colitis
- LSCMMG: Ciclosporin shared care guideline
- LSCMMG: Golimumab
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Methotrexate shared care guideline
- LSCMMG: Primary Care Constipation Guidelines
- LSCMMG: Recommended Biologic Commissioning Pathway
- LSCMMG: Vedolizumab
- LSCMMG: Vedolizumab SC NMR
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing
- MHRA: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions
- MHRA: Thiopurines and intrahepatic cholestasis of pregnancy
- MHRA: Thiopurines and intrahepatic cholestasis of pregnancy
- MHRA: Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies
- MHRA: Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections
- MHRA: Tumour necrosis factor alpha inhibitors
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG147: Diverticular disease: diagnosis and management
- NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
- NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
- NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
- NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
- NICE TA187: Crohns disease - infliximab & adalimumab
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
- NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
- NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
- NICE TA456: Ustekinumab for moderately to severely active Crohn�s disease after previous treatment
- NICE TA456: Ustekinumab for moderately to severely active Crohn�s disease after previous treatment
- NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
- NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
- NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
- NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis
- NICE TA828: Ozanimod for treating moderately to severely active ulcerative colitis
- NICE TA856: Upadacitinib for treating moderately to severely active ulcerative colitis
- NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease
- NICE TA905: Upadacitinib for previously treated moderately to severely active Crohn�s disease
- NICE TA925: Mirikizumab for treating moderately to severely active ulcerative colitis
- NICE TA956: Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over
- NICE TA998: Risankizumab for treating moderately to severely active ulcerative colitis
- NIE TA998: Risankizumab for treating moderately to severely active ulcerative colitis
- SPS: Mesalazine monitoring